Immutep's Efti Shows Promise in Cancer Therapy
Immutep Price Target Cut 6.7% to A$0.70/Share by Bell Potter
Express News | Immutep Shares Are Trading Lower. The Company Announced Efficacy and Safety Results From the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha in Combination With MSD's Anti-PD-1 Therapy KEYTRUDA as First-line Treatment of Recurrent or Metastatic...
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September
JPMorgan Acquires Substantial Stake in Immutep Ltd
Capital One Financial Maintains Immutep(IMMP.US) With Buy Rating, Maintains Target Price $8
